Plus Therapeutics Stock Probability of Future Stock Price Finishing Under 1.08
| PSTV Stock | USD 1.20 0.04 3.23% |
Plus |
Plus Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Plus Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Plus Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Plus Therapeutics generated a negative expected return over the last 90 days | |
| Plus Therapeutics may become a speculative penny stock | |
| Plus Therapeutics has high historical volatility and very poor performance | |
| Plus Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.91 M. Net Loss for the year was (13.32 M) with loss before overhead, payroll, taxes, and interest of (9.47 M). | |
| Plus Therapeutics currently holds about 20.27 M in cash with (12.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. |
Plus Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Plus Stock often depends not only on the future outlook of the current and potential Plus Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Plus Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 3.1 M | |
| Cash And Short Term Investments | 8.6 M |
Plus Therapeutics Technical Analysis
Plus Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Plus Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Plus Therapeutics. In general, you should focus on analyzing Plus Stock price patterns and their correlations with different microeconomic environments and drivers.
Plus Therapeutics Predictive Forecast Models
Plus Therapeutics' time-series forecasting models is one of many Plus Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Plus Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Plus Therapeutics
Checking the ongoing alerts about Plus Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Plus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Plus Therapeutics generated a negative expected return over the last 90 days | |
| Plus Therapeutics may become a speculative penny stock | |
| Plus Therapeutics has high historical volatility and very poor performance | |
| Plus Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.91 M. Net Loss for the year was (13.32 M) with loss before overhead, payroll, taxes, and interest of (9.47 M). | |
| Plus Therapeutics currently holds about 20.27 M in cash with (12.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. |
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.